Gan & Lee

About Gan & Lee

Founded in 1998, Gan & Lee Pharmaceuticals has successfully developed the first Chinese domestic insulin analog. The company has become one of the main suppliers of insulin in China and now strives to broaden its global coverage in the field of diabetes diagnosis and treatment. 


Headquartered in the Tongzhou Economic Development Area, Beijing, China, Gan & Lee has state-of-the-art buildings and GMP facilities. In 2014, it established a US subsidiary in New Jersey, and in 2019, Gan & Lee selected Linyi City, Shandong, China, to become its second domestic drug production site, with further plans to expand to North America, Europe, and other regions.Gan & Lee is ...

  • Country/Region:
    China
  • On CPHI since:
    2021
Contact info
  • No.8 Nanfeng West 1st Street, Huoxian, Tongzhou district, 101109, Beijijng, China
Meet us at

CPHI & PMEC China 2026

Shanghai New International Expo Center
16 Jun 2026 - 18 Jun 2026

CPHI Milan 2026

Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026

Products from Gan & Lee (6)

  • Basalin®(insulin glargine injection)

    Product Basalin®(insulin glargine injection)

    Basalin® is an insulin glargine injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2005 and has been approved in almost 20 countries globally. As a long-acting biosimilar insulin, Basalin® is able to stablely control human blood sugar within 24...
  • GanleeFine®(pen injeciton needle)

    Product GanleeFine®(pen injeciton needle)

    GanleeFine™ is pen needle for single use, collaborately used with insulin pen or prefilled pen for insulin injection. GanleeFine™ has 5 specifications including 0.30x6mm/30G, 0.30x8mm/30G, 0.25x6mm/31G, 0.25x8mm/31G and 0.23x4mm/32G, which can meet different people's injection needs.
  • GanleePen™(reusable insulin pen)

    Product GanleePen™(reusable insulin pen)

    GanleePen is a reusable insulin pen produced by Gan & Lee's wholly-owned subsidiary, Gangan Medical Technology Co., Ltd. It has user-friendly design, big dose window, precise dose and clear reminder for dose adjustment. In addition, GanleePen is made of high-quality and reusable materials. The color of...
  • Prandilin®

    Product Prandilin®

    Prandilin® is an insulin lispro injection developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2007. As a fast-acting biosimilar insulin, Prandilin® is able to rapidly control human blood sugar 15-20mins after injection before a meal for the treatment of d...
  • Prandilin®25

    Product Prandilin®25

    Prandilin®25 is a premix insulin lispro suspension developed and produced independently by Gan & Lee Pharmaceuticals. It was launched in China in 2014. As a fast-acting biosimilar insulin, Prandilin®25 is able to rapidly and stablely control human blood sugar 15-20mins after injection before a mea...
  • Rapilin™

    Product Rapilin™

    Rapilin™ is insulin aspart injection developed and produced independently by Gan & Lee Pharmaceuticals. It was approved in China in 2020. As a fast-acting biosimilar insulin, Rapilin™ is able to rapidly control human blood sugar 5-10 mins after injection before or between or after a meal for the t...

Gan & Lee Resources (1)

  • Video In-Depth CPHI Interview with Gan & Lee: Advancing Pharmaceutical Solutions

    Gai Liu, Director at Gan & Lee Pharmaceuticals, shares the company’s remarkable journey, highlighting key milestones, their diverse product portfolio, and ongoing research initiatives. The interview also provides insights into Gan & Lee's international expansion strategies, talent development, and innovative approaches to staying competitive in the global pharmaceutical landscape.